Advertisement

Association of Medication Adherence and Clinical Outcomes in Sarcoidosis

Published:February 04, 2020DOI:https://doi.org/10.1016/j.chest.2020.01.026

      Background

      Sarcoidosis, one of the most common interstitial lung diseases, has significant health disparities. Approximately 50% of individuals affected with sarcoidosis will undergo spontaneous remission, but those who do not undergo remission often require long-term or lifelong treatment to prevent disease progression. We sought to assess the association between medication adherence and clinical outcomes in sarcoidosis.

      Methods

      Adult patients in the Johns Hopkins Sarcoidosis Clinic diagnosed with pulmonary sarcoidosis on treatment were eligible for enrollment. Questionnaires were administered to assess medication adherence, health-related quality of life (HRQoL), health-care utilization, and sociodemographic information. Clinical information was abstracted from medical charts including lung function, disease duration, comorbidities, and sarcoidosis organ involvement.

      Results

      A total of 117 participants were enrolled (57% women; 55% black; median age, 57 years). Within the cohort, 66% of individuals reported at least one nonadherent behavior. Higher medication adherence was associated with better HRQoL (P < .05). There was no association between medication adherence and the odds of health-care utilization, FVC % predicted, FEV1 % predicted, or diffusion capacity of the lungs for carbon monoxide % predicted. Black participants reported lower medication adherence than white participants (P < .05).

      Conclusions

      This is the first observational study of medication adherence in sarcoidosis. We found that higher medication adherence was associated with better HRQoL, with blacks more likely to report nonadherence. Medication adherence may be an important target to improve patient-reported outcomes and health disparities in sarcoidosis.

      Key Words

      Abbreviations:

      CCI (Charlson Comorbidity Index), Dlco (diffusion capacity of the lungs for carbon monoxide), HRQoL (health-related quality of life), KSQ (King’s Sarcoidosis Health Questionnaire), SGRQ (St. George’s Respiratory Questionnaire)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Chen E.S.
        • Moller D.R.
        Sarcoidosis--scientific progress and clinical challenges.
        Nat Rev Rheumatol. 2011; 7: 457-467
        • Coultas D.B.
        • Zumwalt R.E.
        • Black W.C.
        • Sobonya R.E.
        The epidemiology of interstitial lung diseases.
        Am J Respir Crit Care Med. 1994; 150: 967-972
        • Gerke A.K.
        • Judson M.A.
        • Cozier Y.C.
        • Culver D.A.
        • Koth L.L.
        Disease burden and variability in sarcoidosis.
        Ann Am Thorac Soc. 2017; 14: S421-S428
        • Bradley B.
        • Branley H.M.
        • Egan J.J.
        • et al.
        Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.
        Thorax. 2008; 63: v1-v58
        • Gibson G.J.
        • Prescott R.J.
        • Muers M.F.
        • et al.
        British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.
        Thorax. 1996; 51: 238-247
        • Sabate E.
        Adherence to Long-Term Therapies: Evidence for Action.
        World Health Organization, Geneva, Switzerland2003
        • Suissa S.
        • Ernst P.
        • Benayoun S.
        • Baltzan M.
        • Cai B.
        Low-dose inhaled corticosteroids and the prevention of death from asthma.
        N Engl J Med. 2000; 343: 332-336
        • Vestbo J.
        • Anderson J.A.
        • Calverley P.M.
        • et al.
        Adherence to inhaled therapy, mortality and hospital admission in COPD.
        Thorax. 2009; 64: 939-943
        • Eakin M.N.
        • Bilderback A.
        • Boyle M.P.
        • Mogayzel P.J.
        • Riekert K.A.
        Longitudinal association between medication adherence and lung health in people with cystic fibrosis.
        J Cyst Fibros. 2011; 10: 258-264
        • Kardas P.
        • Lewek P.
        • Matyjaszczyk M.
        Determinants of patient adherence: a review of systematic reviews.
        Front Pharmacol. 2013; 4
        • Gerber B.S.
        • Cho Y.I.
        • Arozullah A.M.
        • Lee S.-Y.D.
        Racial differences in medication adherence: a cross-sectional study of Medicare enrollees.
        Am J Geriatr Pharmacother. 2010; 8: 136-145
        • Cohen J.L.
        • Mann D.M.
        • Wisnivesky J.P.
        • et al.
        Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma.
        Ann Allergy Asthma Immunol. 2009; 103: 325-331
        • Khdour M.R.
        • Hawwa A.F.
        • Kidney J.C.
        • Smyth B.M.
        • McElnay J.C.
        Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD).
        Eur J Clin Pharmacol. 2012; 68: 1365-1373
        • Krauskopf K.
        • Federman A.D.
        • Kale M.S.
        • et al.
        Chronic obstructive pulmonary disease illness and medication beliefs are associated with medication adherence.
        Copd. 2015; 12: 151-164
        • McAdam-Marx C.
        • Bellows B.K.
        • Unni S.
        • et al.
        Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.
        J Manag Care Spec Pharm. 2014; 20: 691-700
        • Barr J.T.
        • Schumacher G.E.
        • Freeman S.
        • LeMoine M.
        • Bakst A.W.
        • Jones P.W.
        American translation, modification, and validation of the St. George's Respiratory Questionnaire.
        Clin Ther. 2000; 22: 1121-1145
        • Guyatt G.H.
        • Townsend M.
        • Keller J.
        • Singer J.
        • Nogradi S.
        Measuring functional status in chronic lung disease: conclusions from a randomized control trial.
        Respir Med. 1989; 83: 293-297
        • Jones P.W.
        • Quirk F.H.
        • Baveystock C.M.
        • Littlejohns P.
        A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.
        Am Rev Respir Dis. 1992; 145: 1321-1327
        • Baughman R.P.
        • Drent M.
        • Kavuru M.
        • et al.
        Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
        Am J Respir Crit Care Med. 2006; 174: 795-802
        • Judson M.A.
        • Baughman R.P.
        • Costabel U.
        • et al.
        Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.
        Eur Respir J. 2014; 44: 1296-1307
        • Patel A.S.
        • Siegert R.J.
        • Creamer D.
        • et al.
        The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status.
        Thorax. 2013; 68: 57-65
        • Van Manen M.J.
        • Wapenaar M.
        • Strookappe B.
        • et al.
        Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population.
        Sarcoidosis Vasc Diffuse Lung Dis. 2016; 33: 75-82
        • Baughman R.P.
        • Sweiss N.
        • Keijsers R.
        • et al.
        Repository corticotropin for chronic pulmonary sarcoidosis.
        Lung. 2017; 195: 313-322
        • Arozullah A.M.
        • Yarnold P.R.
        • Bennett C.L.
        • et al.
        Development and validation of a short-form, rapid estimate of adult literacy in medicine.
        Med Care. 2007; 45: 1026-1033
        • Moller D.R.
        • Koth L.L.
        • Maier L.A.
        • et al.
        Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study. Sarcoidosis protocol.
        Ann Am Thorac Soc. 2015; 12: 1561-1571
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Koneru S.
        • Shishov M.
        • Ware A.
        • et al.
        Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting.
        Arthritis Rheum. 2007; 57: 1000-1006
        • Judson M.A.
        • Chaudhry H.
        • Louis A.
        • Lee K.
        • Yucel R.
        The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis.
        Respir Med. 2015; 109: 526-531
        • Lower E.E.
        • Baughman R.P.
        Prolonged use of methotrexate for sarcoidosis.
        Arch Intern Med. 1994; 155: 846-851
        • Vorselaars A.D.M.
        • Wuyts W.A.
        • Vorselaars V.M.M.
        • et al.
        Methotrexate vs azathioprine in second-line therapy of sarcoidosis.
        Chest. 2013; 144: 805-812
        • Adams A.S.
        • Trinacty C.M.
        • Zhang F.
        • et al.
        Medication adherence and racial differences in A1C control.
        Diabetes Care. 2008; 31: 916-921
        • Le T.T.
        • Bilderback A.
        • Bender B.
        • et al.
        Do asthma medication beliefs mediate the relationship between minority status and adherence to therapy?.
        J Asthma. 2008; 45: 33-37
        • Stirratt M.J.
        • Dunbar-Jacob J.
        • Crane H.M.
        • et al.
        Self-report measures of medication adherence behavior: recommendations on optimal use.
        Transl Behav Med. 2015; 5: 470-482
        • Patel M.
        • Perrin K.
        • Pritchard A.
        • et al.
        Accuracy of patient self-report as a measure of inhaled asthma medication use.
        Respirology. 2013; 18: 546-552
        • Tommelein E.
        • Mehuys E.
        • Van Tongelen I.
        • Brusselle G.
        • Boussery K.
        Accuracy of the Medication Adherence Report Scale (MARS-5) as a quantitative measure of adherence to inhalation medication in patients with COPD.
        Ann Pharmacother. 2014; 48: 589-595
        • Osborn C.Y.
        • Bains S.S.
        • Egede L.E.
        Health literacy, diabetes self-care, and glycemic control in adults with type 2 diabetes.
        Diabetes Technol Therap. 2010; 12: 913-919